ABSTRACT
An 18-year-old man underwent allogenic bone marrow transplantation (BMT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Ph+ALL relapsed 3 months after the first BMT, and the patient underwent a second BMT. However, Ph+ALL relapsed 4 months after the second BMT, and he received a haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) from his father. Molecular complete remission was confirmed 29 days after haplo-PBSCT. However, the patient needed dialysis for end-stage renal disease due to thrombotic microangiopathy 3 years and 2 months after haplo-PBSCT. He received a kidney transplantation from his father 7 years and 10 months after haplo-PBSCT, and got off dialysis after the kidney transplantation. Immunosuppressive therapy with methylprednisolone, tacrolimus, and mycophenolate mofetil was started for kidney transplantation, but the dose of immunosuppressive agents was reduced successfully without rejection soon after kidney transplantation. The patient has maintained long-term remission since the haplo-PBSCT, and his kidney function was restored by the kidney transplantation from his father.
Subject(s)
Graft vs Host Disease , Hematopoietic Stem Cell Transplantation , Kidney Failure, Chronic , Kidney Transplantation , Precursor Cell Lymphoblastic Leukemia-Lymphoma , Male , Humans , Adolescent , Philadelphia Chromosome , Transplantation, Homologous , Bone Marrow Transplantation , Acute Disease , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapyABSTRACT
A 31-year-old man underwent allogeneic bone marrow transplantation (BMT) for the treatment of transfusion-dependent aplastic anemia (AA) after conditioning with a regimen including fludarabine, cyclophosphamide, and antithymocyte globulin. The patient developed a late graft rejection on day 103 and showed autologous hematologic recovery not requiring transfusions on day 76. Peripheral blood leukocytes were of 100% recipient origin on day 103, and paroxysmal nocturnal hematuria (PNH)-type granulocytes were detected 5 months after BMT. The patient suddenly experienced hemolytic symptoms triggered by cold stimulation, and was diagnosed with autoimmune hemolytic anemia (AIHA) 37 months after BMT. Although anemia was ameliorated by prednisolone (PSL), hemolytic attacks repeatedly occurred, which became refractory to corticosteroids. Moreover, the patient underwent a splenectomy for the steroid-resistant AIHA and achieved AIHA remission without the need for PSL at 53 months after BMT. The immune tolerance breakdown to erythrocyte antigens was thought to have occurred due to various factors including immune AA, medication, cold stimulation, and infection, leading to AIHA development in this case.
Subject(s)
Anemia, Aplastic , Anemia, Hemolytic, Autoimmune , Hematopoietic Stem Cell Transplantation , Adult , Anemia, Aplastic/therapy , Anemia, Hemolytic, Autoimmune/diagnosis , Anemia, Hemolytic, Autoimmune/etiology , Anemia, Hemolytic, Autoimmune/therapy , Antilymphocyte Serum/therapeutic use , Hematuria , Hemolysis , Humans , Male , Prednisolone/therapeutic useABSTRACT
Bone turnover markers (BTMs) are useful parameters for assessing fracture risk and unlike bone mineral density (BMD), can be measured at any institution. However, BTM values have not been established in patients post-allogeneic hematopoietic stem cell transplantation (allo-HSCT). We investigated the practicality of BTMs in patients who underwent allo-HSCT by measuring levels of the serum bone resorption marker, tartrate-resistant acid phosphatase-5b (TRACP-5b), and the bone formation marker, bone-specific alkaline phosphatase (BAP), together with BMD, 1 month before and 6 months after allo-HSCT. Patients were classified into either the alendronate group (n = 14) if alendronate treatment (35 mg orally per week) was administered before allo-HSCT or within 1 month after allo-HSCT, or the control group (n = 16), in which patients did not receive alendronate treatment. Despite the high frequency of corticosteroids users in the alendronate group (71.4 vs. 18.9%; p < 0.01), the mean percentage changes in BMD at the lumbar spine (- 2.9 vs. - 3.1%; p = 0.44) and femoral neck (- 3.2 vs. - 4.1%; p = 1.00), TRACP-5b levels (- 4.8 vs. 9.9%; p = 0.45), and BAP levels (6.9 vs. 1.0%; p = 0.85) during 6 months did not differ significantly between the alendronate and control groups. Additionally, the percentage changes in BMD at the lumbar spine were negatively associated with the TRACP-5b levels 6 months after allo-HSCT (p = 0.03, r = 0.40). Our results indicate the possible effectiveness of alendronate treatment in allo-HSCT patients. BTM levels could be useful to monitor the BMD changes.
Subject(s)
Alkaline Phosphatase/blood , Bone Density , Bone Remodeling , Hematopoietic Stem Cell Transplantation , Osteoporosis/blood , Tartrate-Resistant Acid Phosphatase/blood , Adult , Aged , Alendronate/administration & dosage , Allografts , Biomarkers/blood , Female , Humans , Male , Middle Aged , Osteoporosis/drug therapy , Osteoporosis/etiologySubject(s)
Autoantibodies/blood , Paraneoplastic Syndromes/immunology , Pemphigus/immunology , Waldenstrom Macroglobulinemia/complications , Aged , Autoantibodies/immunology , Desmocollins/immunology , Fatal Outcome , Humans , Lip , Male , Mouth Mucosa/immunology , Mouth Mucosa/pathology , Paraneoplastic Syndromes/blood , Paraneoplastic Syndromes/diagnosis , Paraneoplastic Syndromes/pathology , Pemphigus/blood , Pemphigus/diagnosis , Pemphigus/pathology , Tongue , Waldenstrom Macroglobulinemia/blood , Waldenstrom Macroglobulinemia/diagnosis , Waldenstrom Macroglobulinemia/immunologyABSTRACT
A 51-year-old man underwent allogeneic bone marrow transplantation (BMT) for recurrent acute myeloid leukemia. Although the patient developed slight edema, pleural effusion, and cardiac effusion 6 months after BMT, his clinical condition improved with furosemide treatment. The patient was transfused with red blood cells for the management of anemia 8 months after BMT. He developed acute respiratory failure with pulmonary alveolar hemorrhage 80 min after the transfusion. He was diagnosed with transfusion-associated circulatory overload (TACO) due to the presence of acute pulmonary congestion and depressed left ventricular systolic function. Reduced circulatory load due to sufficient furosemide led to ventilator weaning 3 days later. Other causes of pulmonary alveolar hemorrhage were excluded, and the patient's condition improved by cardiac failure treatment only. This clinical course indicated that pulmonary alveolar hemorrhage would breakdown the blood vessels due to acute pulmonary congestion. Chemotherapy and prolonged anemia are high risks for cardiac failure in patients with hematological malignancies. Therefore, the possibility of cardiac failure is considered when patients with hematological malignancies have fluid retention, such as cardiac enlargement, edema, and pleural effusion. Moreover, the body fluids should be monitored before and after blood transfusion.
Subject(s)
Bone Marrow Transplantation/adverse effects , Hemorrhage/etiology , Pulmonary Edema/etiology , Transfusion Reaction , Blood Transfusion , Humans , Male , Middle AgedABSTRACT
Dysregulation of T-cell-mediated immunity is responsible for acquired pure red cell aplasia (PRCA). Although STAT3 mutations are frequently detected in patients with T-cell large granular lymphocytic leukemia (T-LGLL), which is often complicated by PRCA and which is also reported to be associated with acquired aplastic anemia (AA) and myelodysplastic syndrome (MDS), whether STAT3-mutated T cells are involved in the pathophysiology of PRCA and other types of bone marrow failure remains unknown. We performed STAT3 mutation analyses of the peripheral blood mononuclear cells from PRCA patients (n = 42), AA (n = 54), AA-paroxysmal nocturnal hemoglobinuria (AA-PNH; n = 7), and MDS (n = 21) using an allele-specific polymerase chain reaction and amplicon sequencing. STAT3 mutations were not detected in any of the 82 patients with AA/PNH/MDS but were detected in 43% of the 42 PRCA patients. In all 7 STAT3-mutation-positive patients who were studied, the STAT3 mutations were restricted to sorted CD8+ T cells. The prevalence of STAT3 mutation in idiopathic, thymoma-associated, autoimmune disorder-associated, and T-LGLL-associated PRCA was 33% (5 of 15), 29% (2 of 7), 20% (1 of 5), and 77% (10 of 13), respectively. The STAT3-mutation-positive patients were younger (median age, 63 vs 73 years; P= .026) and less responsive to cyclosporine (46% [6 of 13] vs 100% [8 of 8]; P= .0092) in comparison with STAT3-mutation-negative patients. The data suggest that STAT3-mutated CD8+ T cells may be closely involved in the selective inhibition of erythroid progenitors in PRCA patients.
Subject(s)
CD8-Positive T-Lymphocytes/metabolism , Red-Cell Aplasia, Pure/genetics , STAT3 Transcription Factor/genetics , Female , Humans , Male , Mutation , Red-Cell Aplasia, Pure/metabolismABSTRACT
A 45-year-old man presented with fatigue and pain in the finger joints. Despite having a history of suspected sideroblastic anemia since the age of 18 years, he had not been followed up for years. Upon presentation, laboratory data revealed microcytic anemia and elevated serum ferritin levels. In addition, ringed sideroblasts were increased in the bone marrow. A liver biopsy revealed hemochromatosis and cirrhosis. Furthermore, genetic analysis revealed that he harbored the ALAS2 R452H mutation, leading to the diagnosis of X-linked sideroblastic anemia (XLSA). Accordingly, oral folate or vitamin (Vit) B12 was administered, but his anemia did not respond. However, his hemoglobin level increased from 7 to 11 g/dl with an additional prescription of oral VitB6, which facilitated the patient to undergo phlebotomy to ameliorate organ dysfunctions caused by iron overload. Previous research has revealed that ALAS2 R452 mutations confer poor responses to VitB6 therapy. Hence, accrual of patients with an unexpectedly better response, which was observed in our case, may help elucidate the pathogenesis of and therapies for XLSA.
Subject(s)
Anemia, Sideroblastic/therapy , Genetic Diseases, X-Linked/therapy , Vitamin B 6/therapeutic use , 5-Aminolevulinate Synthetase/genetics , Anemia, Sideroblastic/genetics , Genetic Diseases, X-Linked/genetics , Humans , Male , Middle Aged , MutationABSTRACT
Fluconazole (FLCZ) is an azole antifungal agent and it has shown excellent clinical activities in suppressing fungemia with Candida albicans after hematopoietic stem cell transplantation. Increased administration of prophylactic FLCZ seems to have given rise to the relatively higher incidence of more resistant Candida non-albicans infection. We present a case with a rare breakthrough fungemia with C. guilliermondii after cord blood transplantation for Extranodal NK cell Lymphoma, nasal type (ENKL), during antifungal prophylaxis with FLCZ. High level of caution is needed for the breakthrough, especially after long-term azole administration.
Subject(s)
Antibiotic Prophylaxis/adverse effects , Antifungal Agents/therapeutic use , Candida/physiology , Candidemia/drug therapy , Candidiasis, Invasive/drug therapy , Cord Blood Stem Cell Transplantation/adverse effects , Lymphoma, Extranodal NK-T-Cell/surgery , Pregnancy Complications, Infectious/drug therapy , Adult , Candida/drug effects , Candida/isolation & purification , Candidemia/complications , Candidemia/microbiology , Candidemia/prevention & control , Candidiasis, Invasive/complications , Candidiasis, Invasive/microbiology , Candidiasis, Invasive/prevention & control , Drug Resistance, Multiple, Fungal/drug effects , Female , Fluconazole/adverse effects , Humans , Microbial Sensitivity Tests , Pregnancy , Pregnancy Complications, Infectious/microbiology , Pregnancy Complications, Infectious/prevention & control , Stillbirth , Young AdultABSTRACT
Eculizumab is the complement inhibitor administered to ameliorate intravascular hemolysis in paroxysmal nocturnal hemoglobinuria. Whether or not the inhibitory mechanism may also increase the susceptibility to non-Neisserial infection is unclear. A 73-year old woman presented with bacteremia, cholecystitis and liver abscess with Pseudomonas aeruginosa. Although she had been neutropenic for 21 years, she had no history of severe infection before eculizumab had been administered. The infection with P. aeruginosa was successfully controlled with antibiotics, granulocyte colony-stimulating factor and cholecystectomy. The present case might be representative of less common bacterial infections than Neisseria spp. among patients treated with eculizumab.
Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Bacteremia/drug therapy , Cholecystectomy , Granulocyte Colony-Stimulating Factor/therapeutic use , Hemoglobinuria, Paroxysmal/drug therapy , Pseudomonas aeruginosa/isolation & purification , Aged , Bacteremia/microbiology , Female , Humans , Pseudomonas Infections , Treatment OutcomeSubject(s)
Anemia, Aplastic/complications , Anemia, Refractory, with Excess of Blasts/complications , Hematopoietic Stem Cell Transplantation/adverse effects , Polycythemia/etiology , Adult , Anemia, Aplastic/therapy , Anemia, Refractory, with Excess of Blasts/therapy , Child , Female , Humans , Male , Middle Aged , Polycythemia/pathology , Prognosis , Transplantation, Homologous , Young AdultABSTRACT
The prognosis for adult acute lymphoblastic leukemia (ALL) patients with central nervous system (CNS) involvement (CNS+) who received allogeneic hematopoietic stem cell transplantation (allo-SCT) remains unclear. We retrospectively compared the outcomes of allo-SCT for patients with CNS involvement and for patients without CNS involvement (CNS-) using a database in Japan. The eligibility criteria for this study were as follows: diagnosis of ALL, aged more than 16 years, allo-SCT between 2005 and 2012, and first SCT. Data for 2582 patients including 136 CNS+ patients and 2446 CNS- patients were used for analyses. As compared with CNS- patients, CNS+ patients were younger, had worse disease status at SCT and had poorer performance status (PS) at SCT (P < 0.01). Incidence of relapse was higher in CNS+ patients (P = 0.02), and incidence of CNS relapse was also higher (P < 0.01). The probability of 3-year overall survival (OS) was better in CNS- patients (P < 0.01) by univariate analysis. However, in patients who received SCT in CR, there was no difference in the probability of OS between CNS+ and CNS- patients (P = 0.38) and CNS involvement did not have an unfavorable effect on OS by multivariate analysis. CNS+ patients who achieved CR showed OS comparable to that of CNS- patients.
Subject(s)
Central Nervous System Neoplasms/mortality , Central Nervous System Neoplasms/therapy , Databases, Factual , Hematopoietic Stem Cell Transplantation , Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Registries , Adolescent , Adult , Aged , Allografts , Central Nervous System Neoplasms/diagnosis , Disease-Free Survival , Female , Humans , Japan/epidemiology , Male , Middle Aged , Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Survival RateSubject(s)
Brain/pathology , Hematopoietic Stem Cell Transplantation/adverse effects , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/surgery , Toxoplasma/isolation & purification , Toxoplasmosis, Cerebral/cerebrospinal fluid , Toxoplasmosis, Cerebral/pathology , Transplantation Conditioning/adverse effects , Adult , Anti-Bacterial Agents/therapeutic use , Antibiotic Prophylaxis/methods , Biopsy , Brain/diagnostic imaging , Brain/surgery , Cyclophosphamide/therapeutic use , Fever/etiology , Headache/etiology , Humans , Magnetic Resonance Imaging , Male , Myeloablative Agonists/therapeutic use , Polymerase Chain Reaction , Toxoplasmosis, Cerebral/drug therapy , Toxoplasmosis, Cerebral/microbiology , Transplantation Conditioning/methods , Transplantation, Homologous/adverse effects , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , Vomiting/etiologyABSTRACT
Pyomyositis is classified into two main types: tropical and non-tropical. Non-tropical pyomyositis occurs among various immunocompromised patients, and Staphylococcus aureus has been reported as the most common pathogen. Pyomyositis caused by Streptococcus pneumoniae is uncommon, and has not been previously reported after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Here, we report a unique case with pyomyositis caused by S. pneumoniae in the bilateral erector spinae muscles 34 months after allo-HSCT. The patient had an initial clinical response following the administration of intravenous benzylpenicillin potassium for 4 weeks. Although S. pneumoniae bacteremia is a rare bacterial infection after HSCT, the possibility of pyomyositis must be considered when a recipient develops S. pneumoniae bacteremia. Accurate diagnosis and the selection of appropriate antibiotics are necessary for the treatment of pyomyositis.
Subject(s)
Hematopoietic Stem Cell Transplantation/adverse effects , Pyomyositis/etiology , Pyomyositis/microbiology , Staphylococcal Infections/complications , Streptococcus pneumoniae/pathogenicity , Adult , Anti-Bacterial Agents/therapeutic use , Bacteremia/drug therapy , Bacteremia/etiology , Bacteremia/microbiology , Humans , Male , Pyomyositis/drug therapy , Staphylococcal Infections/drug therapy , Streptococcus pneumoniae/drug effectsSubject(s)
Graft vs Host Disease/drug therapy , Hematopoietic Stem Cell Transplantation/adverse effects , Mycophenolic Acid/therapeutic use , Skin Diseases, Infectious/drug therapy , Steroids/therapeutic use , Acute Disease , Anti-Bacterial Agents/therapeutic use , Female , Graft vs Host Disease/diagnosis , Graft vs Host Disease/etiology , Humans , Male , Skin Diseases, Infectious/diagnosis , Skin Diseases, Infectious/etiology , Transplantation, Homologous/adverse effects , Treatment OutcomeABSTRACT
An 84-year-old woman was referred to our hospital presenting anemia. Her hemoglobin level was 5.8 g/dL, and white blood cell count was 9400/µL, consisting of 82% lymphocytes. Given the lymphocyte phenotype (CD2+, CD3-, CD16+, and CD56-) and negative whole blood EBV viral load, we made a diagnosis of chronic lymphoproliferative disorder of NK cells (CLPD-NK). We suspected hemolytic anemia because of the high levels of reticulocytes in the peripheral blood and the low haptoglobin value. Although the direct Coombs test was negative and there was no cold agglutination, we examined her red-blood-cell-bound IgG (RBC-IgG), which was elevated. She was diagnosed as having as Coombs-negative autoimmune hemolytic anemia (AIHA). We report the effectiveness of oral cyclophosphamide for Coombs-negative autoimmune hemolytic anemia in CLPD-NK.
Subject(s)
Anemia, Hemolytic, Autoimmune , Cyclophosphamide/administration & dosage , Killer Cells, Natural/metabolism , Lymphoproliferative Disorders , Aged, 80 and over , Anemia, Hemolytic, Autoimmune/blood , Anemia, Hemolytic, Autoimmune/diagnosis , Anemia, Hemolytic, Autoimmune/drug therapy , Autoantibodies/blood , CD56 Antigen/blood , Chronic Disease , Female , GPI-Linked Proteins/blood , Humans , Immunoglobulin G/blood , Lymphoproliferative Disorders/blood , Lymphoproliferative Disorders/diagnosis , Lymphoproliferative Disorders/drug therapy , Receptors, IgG/blood , Reticulocytes/metabolismABSTRACT
Recent reports suggested that central nervous system (CNS) involvement (CNS+) in patients with acute myeloid leukemia (AML) before allogeneic hematopoietic stem cell transplantation (allo-HSCT) is not an independent predictor of survival after allo-HSCT. However, these studies did not analyze minimal residual disease in the CNS at the time of allo-HSCT. We evaluated the effect of residual CNS+ on the transplant outcomes of 214 AML patients in a single institution. Twenty-one (10%) patients were diagnosed with CNS+ prior to allo-HSCT. Of these, 13 patients had CNS disease at the time of allo-HSCT. The patients in CNS+ AML remission at the time of allo-HSCT had better overall survival (OS) than the patients who were not in remission (2-year OS: 55% vs. 7.7%, p = 0.0001). In multivariate analyses, CNS+ at the time of allo-HSCT (hazard ratio (HR), 1.9; 95% confidence interval (CI), 1.05-3.59; p = 0.04), age over 50 years at the time of allo-HSCT, and non-complete remission disease status in bone marrow at the time of allo-HSCT were independent adverse factors for OS. However, a prior history of CNS+ before allo-HSCT did not independently affect OS (HR, 1.27; 95% CI 0.53-2.07; p = 0.6). Early diagnosis and eradication of CNS+ at the time of allo-HSCT may be necessary to improve the outcome for patients with CNS+ AML.
Subject(s)
Central Nervous System Neoplasms/genetics , Central Nervous System Neoplasms/pathology , Hematopoietic Stem Cell Transplantation/adverse effects , Leukemia, Myeloid, Acute/pathology , Transplantation, Homologous/adverse effects , Acute Disease , Adolescent , Adult , Aged , Bone Marrow/pathology , Female , Humans , Male , Middle Aged , Neoplasm, Residual/pathology , Remission Induction , Young AdultABSTRACT
A 60-year-old man with myelodysplastic syndrome underwent allogeneic transplantation of female umbilical cord blood in 2010 and sustained a complete remission. He experienced severe pain in his left hip joint and was admitted to the orthopedic surgery division of our institution in February 2015. After admission, he was suspected to have hemophagocytic syndrome (HPS) and was thus transferred to the hematology division. Bone marrow aspiration revealed hyper-cellular marrow filled with abnormal collapsed cells, consistent with bone marrow necrosis (BMN). As there was no evidence of infection, collagen disease, or occult cancer, he was diagnosed with HPS of unknown origin and treated with dexamethasone, cyclosporine A, and etoposide according to the HLH-2004 protocol. Although his general condition and laboratory findings showed amelioration, morphologically abnormal cells appeared in peripheral blood two weeks after treatment. Bone marrow aspiration showed BMN with increased abnormal cells, positive for CD117 and MPO. Sex chromosome FISH analysis revealed donor chimerism and cytogenetic analysis showed 46XX, +1, der (1;7) (q10;q10). He was diagnosed with donor cell leukemia (DCL) and received salvage chemotherapy. However, he died because of severe pneumonia and sepsis without neutrophil recovery at day 68. We herein report this rare case of DCL with BMN.
Subject(s)
Bone Marrow Diseases/complications , Bone Marrow Diseases/pathology , Fractures, Bone/etiology , Leukemia/therapy , Fatal Outcome , Hematopoietic Stem Cell Transplantation , Humans , Lymphohistiocytosis, Hemophagocytic , Male , Middle Aged , Necrosis/complications , Tissue DonorsABSTRACT
BACKGROUND: Granulocyte-colony stimulating factor (G-CSF) is widely used to mobilize peripheral blood stem cells (PBSCs) in healthy donors. A few reports have shown that some healthy donors developed acute respiratory distress syndrome or capillary leak syndrome after more than several rounds of G-CSF administration or leukapheresis. CASE REPORT: We report the case of a healthy donor for allogeneic stem cell transplantation who developed severe hypoxemia 1 h after only the first administration of G-CSF. The donor was administered 10 µg/kg G-CSF (lenograstim) subcutaneously for PBSC mobilization. 1 h after the first administration of G-CSF, the donor suddenly presented with dry cough and dyspnea. The oxygen saturation by pulse oximetry (SpO2) in the room air was 88%. An electrocardiogram and chest radiography revealed no abnormalities. We excluded other causes of severe hypoxemia and diagnosed the donor with hypoxemia due to G-CSF administration, which was subsequently terminated. The donor was administered 2 l/min oxygen via a nasal cannula and 100 mg hydrocortisone intravenously. He subsequently recovered, and SpO2 in the room air returned to 98% 10 h after hypoxemia. CONCLUSION: These respiratory symptoms might be related to anaphylactoid or hypersensitivity reaction. The donors should be observed for at least 1 h after the first administration of G-CSF.
ABSTRACT
Nocardiosis is a rare bacterial infection occurring mainly in patients with deficient cell-mediated immunity. Although disseminated nocardiosis after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a rare complication, it is associated with high mortality. Moreover, after allo-HSCT, nocardiosis may be mistaken for other bacterial or fungal infections because clinical and radiographic findings of pulmonary, cerebral, and cutaneous nocardiosis lesions are non-specific. Here, we report a case of disseminated nocardiosis (caused by Nocardia abscessus) with skin, pulmonary, liver, lymph node, and multiple brain abscesses in a patient after allo-HSCT. The patient initially responded clinically and radiographically to imipenem/cilastin and trimethoprim-sulfamethoxazole therapy. Clinicians should be aware of the possibility of nocardiosis in allo-HSCT recipients who are treated with multiple immunosuppressive agents to control chronic graft-versus-host disease. Accurate diagnosis and identification of disseminated nocardiosis is important to ensure administration of the correct antibiotic regimen.
Subject(s)
Bone Marrow Transplantation/adverse effects , Graft vs Host Disease/drug therapy , Hematopoietic Stem Cell Transplantation/adverse effects , Immunosuppressive Agents/adverse effects , Leukemia, Myeloid, Acute/surgery , Nocardia Infections/diagnostic imaging , Nocardia Infections/drug therapy , Nocardia/isolation & purification , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Antibiotic Prophylaxis , Antineoplastic Agents/therapeutic use , Brain Abscess/cerebrospinal fluid , Brain Abscess/diagnostic imaging , Brain Abscess/drug therapy , Brain Abscess/microbiology , Bronchoalveolar Lavage , Bronchoalveolar Lavage Fluid/microbiology , Bronchoscopy , Colitis/virology , Cytomegalovirus/isolation & purification , Female , Humans , Immunocompromised Host , Immunosuppressive Agents/therapeutic use , Leukemia, Myeloid, Acute/drug therapy , Liver/microbiology , Lung/diagnostic imaging , Lung/microbiology , Magnetic Resonance Imaging , Middle Aged , Nocardia Infections/cerebrospinal fluid , Nocardia Infections/microbiology , Skin/microbiology , Tomography, X-Ray Computed , Transplantation, Homologous/adverse effects , Unrelated DonorsABSTRACT
A 58-year-old female was diagnosed with Philadelphia chromosome positive chronic myeloid leukemia (CML) in blast crisis (BC) in 2004. The patient received imatinib, which quickly induced molecular remission, and subsequently underwent bone marrow transplantation (BMT) from an unrelated human leukocyte antigen (HLA)-identical donor. The post-transplant clinical course was essentially uneventful. In 2014, ten years after the BMT, the patient was admitted to our hospital complaining of lymphadenopathy, and blasts were observed in peripheral blood. The patient was diagnosed as having a CML relapse in myeloid BC, with leukemic infiltration in lymph nodes, and was treated with dasatinib. Subsequently, pleural effusion developed and nilotinib was administered, which induced normal blood counts without blasts and partial cytogenetic remission, one month after administration. Six months after the relapse, this patient underwent a second BMT from an HLA-matched unrelated donor. Recent studies have demonstrated the cumulative incidence of CML relapse more than five years after allogeneic hematopoietic stem cell transplantation (allo-HSCT) to be higher than in acute myeloid leukemia. Although rare, the possibility of late relapse should be considered in patients diagnosed with CML after allo-HSCT.